600267 海正药业
已收盘 01-13 15:00:00
资讯
新帖
简况
海正药业(600267)披露拟设立宠物处方食品合资公司,1月12日股价下跌1.13%
证券之星 · 01-12 22:34
海正药业(600267)披露拟设立宠物处方食品合资公司,1月12日股价下跌1.13%
每周股票复盘:海正药业(600267)回购进展及子公司上市动态
证券之星 · 01-11 02:57
每周股票复盘:海正药业(600267)回购进展及子公司上市动态
博锐生物冲刺港股:9个月营收14亿净利1.2亿 PAG与海正药业是股东
雷递网 · 01-07
博锐生物冲刺港股:9个月营收14亿净利1.2亿 PAG与海正药业是股东
海正药业最新公告:参股子公司博锐生物递交H股上市申请
证券之星 · 01-06
海正药业最新公告:参股子公司博锐生物递交H股上市申请
海正药业(600267)披露持股5%以上股东拟通过公开征集转让方式协议转让公司股份,1月05日股价上涨3.24%
证券之星 · 01-05
海正药业(600267)披露持股5%以上股东拟通过公开征集转让方式协议转让公司股份,1月05日股价上涨3.24%
每周股票复盘:海正药业(600267)HS387片获FDA临床试验批准
证券之星 · 2025-12-28
每周股票复盘:海正药业(600267)HS387片获FDA临床试验批准
海正药业(600267)披露拟转让全资子公司100%股权议案,12月26日股价下跌0.49%
证券之星 · 2025-12-26
海正药业(600267)披露拟转让全资子公司100%股权议案,12月26日股价下跌0.49%
海正药业(600267)披露获得药品补充申请批准通知书,12月23日股价下跌0.79%
证券之星 · 2025-12-23
海正药业(600267)披露获得药品补充申请批准通知书,12月23日股价下跌0.79%
海正药业(600267.SH)子公司获得兽药产品批准文号批件
智通财经 · 2025-12-23
海正药业(600267.SH)子公司获得兽药产品批准文号批件
海正药业(600267.SH):HS387片获得美国FDA新药临床试验批准通知
智通财经 · 2025-12-22
海正药业(600267.SH):HS387片获得美国FDA新药临床试验批准通知
海正药业(600267.SH)子公司获得新兽药注册证书
智通财经 · 2025-12-18
海正药业(600267.SH)子公司获得新兽药注册证书
海正药业(600267)披露拟转让全资子公司股权议案,12月17日股价上涨0.6%
证券之星 · 2025-12-17
海正药业(600267)披露拟转让全资子公司股权议案,12月17日股价上涨0.6%
海正药业(600267.SH)子公司依维莫司原料药获得CEP证书
智通财经 · 2025-12-12
海正药业(600267.SH)子公司依维莫司原料药获得CEP证书
海正药业(600267)披露全资子公司股权转让进展,12月10日股价上涨0.29%
证券之星 · 2025-12-10
海正药业(600267)披露全资子公司股权转让进展,12月10日股价上涨0.29%
执着追逐风口,69岁的海正药业仍要豪赌“多元化”
蓝鲸财经 · 2025-12-09
执着追逐风口,69岁的海正药业仍要豪赌“多元化”
海正药业(600267.SH)子公司获得兽药产品批准文号批件
智通财经 · 2025-12-05
海正药业(600267.SH)子公司获得兽药产品批准文号批件
海正药业(600267.SH)子公司通过药品GMP符合性检查
智通财经 · 2025-12-03
海正药业(600267.SH)子公司通过药品GMP符合性检查
海正药业(600267)披露第四次以集中竞价交易方式回购公司股份的进展公告,12月01日股价下跌0.1%
证券之星 · 2025-12-01
海正药业(600267)披露第四次以集中竞价交易方式回购公司股份的进展公告,12月01日股价下跌0.1%
每周股票复盘:海正药业(600267)拟投建宠物处方粮项目
证券之星 · 2025-11-23
每周股票复盘:海正药业(600267)拟投建宠物处方粮项目
海正药业最新公告:控股子公司拟投建宠物处方粮项目
证券之星 · 2025-11-19
海正药业最新公告:控股子公司拟投建宠物处方粮项目
加载更多
公司概况
公司名称:
浙江海正药业股份有限公司
所属行业:
医药制造业
上市日期:
2000-07-25
主营业务:
浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是海博麦布片(赛斯美)、注射用哌拉西林钠他唑巴坦钠(特治星)、盐酸米诺环素胶囊(玫满)、瑞舒伐他汀钙片(海舒严)、注射用丝裂霉素、氨氯地平阿托伐他汀钙片(多达一)、丁二磺酸腺苷蛋氨酸肠溶片(喜美欣)、奥利司他、米尔贝肟吡喹酮片(海乐妙)、注射用丁二磺酸腺苷蛋氨酸(喜美欣)。近年来先后承担国家重大新药创制专项课题50余项,获省部级以上科技进步奖10多项,7项发明专利荣获“中国专利优秀奖”,入围浙江省级“科改企业”培育名单。截至报告期末,公司共实现专利申请1481项(国内申请893项,PCT国际申请211项),其中发明专利1376项,实用新型专利99项,外观设计专利6项;拥有授权有效专利508项,其中发明专利413项,实用新型专利90项,外观设计专利5项。报告期内,公司获得工业和信息化部颁发的“国家技术创新示范企业”、浙江省国资委颁发的“2024年度浙江省优秀科改企业”,海正合成生物学项目成功入选浙江省经信厅2025年新兴产业集群强链补链(“415X”集群新质生产力)项目名单。
发行价格:
11.83
{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"海正药业","latestPrice":10.59,"timestamp":1768287601000,"preClose":10.54,"halted":0,"volume":18795972,"delay":0,"changeRate":0.0047,"floatShares":1198000000,"shares":1199000000,"eps":0.4562,"marketStatus":"已收盘","change":0.05,"latestTime":"01-13 15:00:00","open":10.62,"high":10.77,"low":10.55,"amount":200000000,"amplitude":0.0209,"askPrice":10.6,"askSize":238,"bidPrice":10.59,"bidSize":989,"shortable":0,"etf":0,"ttmEps":0.4562,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.54,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":11.59,"lowLimit":9.49,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1198848196,"isCdr":false,"pbRate":1.49,"roa":"--","peRate":23.213503,"roe":"5.47%","epsLYR":0.52,"committee":0.150104,"marketValue":12696000000,"turnoverRate":0.0157,"status":0,"floatMarketCap":12689000000},"requestUrl":"/m/hq/s/600267","defaultTab":"news","newsList":[{"id":"2602296546","title":"海正药业(600267)披露拟设立宠物处方食品合资公司,1月12日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602296546","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602296546?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:34","pubTimestamp":1768228453,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘,海正药业报收于10.54元,较前一交易日下跌1.13%,最新总市值为126.36亿元。该股当日开盘10.66元,最高10.72元,最低10.45元,成交额达2.06亿元,换手率为1.63%。公司近日发布公告,称其第十届董事会第十二次会议审议通过相关议案。其中一项内容为:控股子公司海正动保与中誉宠食共同出资5000万元设立合资公司,海正动保持股60%,中誉宠食持股40%,合资公司将主要从事宠物处方食品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0060","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2602535110","title":"每周股票复盘:海正药业(600267)回购进展及子公司上市动态","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535110?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:57","pubTimestamp":1768071428,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,海正药业报收于10.66元,较上周的9.89元上涨7.79%。本周关注点公司公告汇总:截至2025年12月底,海正药业已回购股份7,216,100股,占总股本的0.60%,支付金额67,992,848.98元。海正药业于2026年1月7日公告,其参股子公司浙江博锐生物制药股份有限公司已于2026年1月6日向香港联合交易所有限公司递交首次公开发行H股并在主板上市的申请,并已在港交所网站刊登申请资料。截至公告日,海正药业持有博锐生物39.62%的股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0188","600267","BK0239"],"gpt_icon":0},{"id":"2601844606","title":"博锐生物冲刺港股:9个月营收14亿净利1.2亿 PAG与海正药业是股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844606","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601844606?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:35","pubTimestamp":1767746126,"startTime":"0","endTime":"0","summary":"浙江博锐生物制药股份有限公司(简称:“博锐生物”)日前递交招股书,准备在港交所上市。博锐生物2025年前9个月营收为13.79亿元,毛利为10.25亿元,经营利润为1.66亿,净利为1.22亿,经调整EBITDA为3.1亿元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260107/6390337170609707116746952.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260107/6390337170609707116746952.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32303/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["600267","PAG"],"gpt_icon":0},{"id":"2601891333","title":"海正药业最新公告:参股子公司博锐生物递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2601891333","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601891333?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:29","pubTimestamp":1767698970,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,参股子公司浙江博锐生物制药股份有限公司已向香港联交所递交首次公开发行境外上市股份(H股)并在香港联交所主板上市的申请,并在香港联交所网站刊登了申请资料。博锐生物是国内领先的聚焦免疫疗法的生物制药公司,海正药业持有其39.62%的股份。博锐生物本次发行尚需取得相关监管机构、证券交易所的批准、核准或备案,存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600037042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","600267","BK0028","BK0188"],"gpt_icon":0},{"id":"2601800018","title":"海正药业(600267)披露持股5%以上股东拟通过公开征集转让方式协议转让公司股份,1月05日股价上涨3.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800018","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601800018?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:15","pubTimestamp":1767608105,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,海正药业报收于10.21元,较前一交易日上涨3.24%,最新总市值为122.4亿元。同日,公司发布公告称,持股5%以上股东浙江省国际贸易集团有限公司拟通过公开征集转让方式协议转让其持有的公司股份72,673,907股,占公司总股本的6.06%,股份性质为无限售条件流通股。本次转让不会导致公司控股股东及实际控制人变更。转让需取得国有资产监督管理部门批准,后续进展存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0060","BK0028","600267"],"gpt_icon":0},{"id":"2594046244","title":"每周股票复盘:海正药业(600267)HS387片获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2594046244","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594046244?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:24","pubTimestamp":1766863451,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,海正药业报收于10.11元,较上周的10.29元下跌1.75%。本周关注点公司公告汇总:HS387片获美国FDA新药临床试验批准,拟用于治疗晚期实体瘤。公司公告汇总浙江海正药业股份有限公司近日收到美国食品药品监督管理局通知,公司申报的HS387片新药临床试验申请已获批准,可在美开展临床试验。该药已获中国国家药品监督管理局临床试验批准。药物后续仍需开展多项临床试验并经审批,短期内对公司经营无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","BK0028","600267"],"gpt_icon":0},{"id":"2594229410","title":"海正药业(600267)披露拟转让全资子公司100%股权议案,12月26日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594229410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594229410?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:31","pubTimestamp":1766759477,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,海正药业报收于10.11元,较前一交易日下跌0.49%,最新总市值为121.2亿元。该股当日开盘10.16元,最高10.18元,最低10.08元,成交额达6138.51万元,换手率为0.51%。根据公告内容,公司拟转让全资子公司浙江省医药工业有限公司100%股权,交易通过产权交易所公开挂牌,广州医药股份有限公司以50,050.00万元摘牌并签署股权交易合同。此次股东会将于2026年1月5日召开,会议将审议上述议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0188","BK0060","BK0239","BK0028"],"gpt_icon":0},{"id":"2593632416","title":"海正药业(600267)披露获得药品补充申请批准通知书,12月23日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593632416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593632416?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:40","pubTimestamp":1766500819,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘,海正药业报收于10.08元,较前一交易日下跌0.79%,最新总市值为120.84亿元。该股当日开盘10.18元,最高10.25元,最低10.06元,成交额达7336.9万元,换手率为0.6%。公司近日发布公告称,浙江海正药业股份有限公司收到国家药监局核准签发的依维莫司片《药品补充申请批准通知书》,同意在原有5mg规格基础上增加2.5mg规格,批准文号为国药准字H20258293,有效期至2030年1月1日。该产品按新4类获批,视同通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300040943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600267","BK0028","BK0239","BK0060"],"gpt_icon":0},{"id":"2593493078","title":"海正药业(600267.SH)子公司获得兽药产品批准文号批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2593493078","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593493078?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:16","pubTimestamp":1766481382,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司控股子公司浙江海正动物保健品有限公司(简称“海正动保公司”)、海正动保公司全资子公司云南生物制药有限公司(简称“云南生物”)分别收到中华人民共和国农业农村部核准签发的盐酸多西环素片、猪瘟病毒E2蛋白重组杆状病毒灭活疫苗(WH-09株)兽药产品批准文号批件。本次海正动保公司、云南生物分别获得盐酸多西环素片、猪瘟病毒E2蛋白重组杆状病毒灭活疫苗(WH-09株)兽药产品批准文号,将进一步丰富公司在兽用药、兽用疫苗产品线和产品结构,有利于进一步推动公司在兽药、兽用疫苗板块的战略布局,提升公司市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","600267","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2593887734","title":"海正药业(600267.SH):HS387片获得美国FDA新药临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2593887734","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593887734?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:01","pubTimestamp":1766394103,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司收到美国食品药品监督管理局(简称“美国FDA”)的通知,由公司申报的HS387片药品临床试验申请已获得美国FDA批准,可以在美国开展临床试验。HS387片是一款由公司自主研发的选择性KIF18A抑制剂,拟用于高级别浆液性卵巢癌、非小细胞肺癌等晚期实体瘤治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海正药业(600267.SH):HS387片获得美国FDA新药临床试验批准通知","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"gpt_icon":0},{"id":"2592354979","title":"海正药业(600267.SH)子公司获得新兽药注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2592354979","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592354979?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:04","pubTimestamp":1766048654,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司控股子公司浙江海正动物保健品有限公司(简称“海正动保公司”)收到中华人民共和国农业农村部核准签发的甲泼尼龙片(犬用)《新兽药注册证书》,该新兽药产品正式获批五类新兽药。本次海正动保公司甲泼尼龙片(犬用)产品获得五类《新兽药注册证书》,标志着上述产品已符合《兽药管理条例》和《兽药注册办法》相关规定,有利于进一步推动公司在兽药板块的战略布局,提升公司市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","BK0060","BK0239","600267"],"gpt_icon":0},{"id":"2592165919","title":"海正药业(600267)披露拟转让全资子公司股权议案,12月17日股价上涨0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592165919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592165919?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:31","pubTimestamp":1765981868,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘,海正药业报收于10.09元,较前一交易日上涨0.6%,最新总市值为120.96亿元。该股当日开盘10.08元,最高10.13元,最低10.0元,成交额达8971.77万元,换手率为0.74%。公司近日发布公告称,将于2026年1月5日召开2026年第一次临时股东会,会议将审议关于签署转让全资子公司浙江省医药工业有限公司100%股权相关合同的议案。登记时间为2025年12月31日,参会股东需提前办理登记手续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","600267","BK0028"],"gpt_icon":0},{"id":"2590714015","title":"海正药业(600267.SH)子公司依维莫司原料药获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590714015","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590714015?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:49","pubTimestamp":1765529372,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业 发布公告,近日,公司全资子公司海正药业杭州有限公司收到欧洲药品质量管理局签发的依维莫司原料药欧洲药典适用性认证证书。本次海正杭州公司依维莫司原料药获得CEP认证证书,显示欧洲规范市场对该原料药质量的认可和肯定,标志此产品具备以原料药形式进入欧盟及承认CEP 证书的其他市场的资质,为公司进一步拓展国际市场带来积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600267","BK0028","BK0188","BK0060","BK0239"],"gpt_icon":0},{"id":"2590538044","title":"海正药业(600267)披露全资子公司股权转让进展,12月10日股价上涨0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538044?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:20","pubTimestamp":1765376412,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘,海正药业报收于10.44元,较前一交易日上涨0.29%,最新总市值为125.16亿元。该股当日开盘10.42元,最高10.45元,最低10.35元,成交额达7383.26万元,换手率为0.59%。公司近日发布公告称,关于转让全资子公司浙江省医药工业有限公司100%股权的公开挂牌事项取得进展。2025年12月10日,公司收到台交所通知,确认广州医药股份有限公司为受让方,成交价格为50,050万元,已缴纳保证金8,600万元。公司将根据进展情况及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600267","BK0028","BK0239","BK0060"],"gpt_icon":0},{"id":"2590935403","title":"执着追逐风口,69岁的海正药业仍要豪赌“多元化”","url":"https://stock-news.laohu8.com/highlight/detail?id=2590935403","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590935403?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:07","pubTimestamp":1765246071,"startTime":"0","endTime":"0","summary":"合作初期,辉瑞将其专利过期的抗生素药物“特治星”授予海正辉瑞独家生产,该药成为公司重要的利润增长点。2017年,辉瑞通过股权转让彻底退出,海正药业失去了重要增长引擎。与辉瑞的分手对海正药业造成了长期负面影响。随着国家带量采购政策的推进,仿制药价格大幅下降,海正药业再次陷入困境。2025年前三季度,海正药业营收为79.23亿元,同比微增0.61%,虽然终结了自2022年以来的连续下滑态势,但归母净利润仅为4.61亿元,同比下滑10.55%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765165796337267393","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","BK0060","BK0188","600267","BK0028"],"gpt_icon":0},{"id":"2589608148","title":"海正药业(600267.SH)子公司获得兽药产品批准文号批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2589608148","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589608148?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:37","pubTimestamp":1764923848,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司控股子公司浙江海正动物保健品有限公司的全资子公司云南生物制药有限公司(简称“云南生物”)收到中华人民共和国农业农村部核准签发的猪支原体肺炎灭活疫苗(GD0503株)兽药产品批准文号批件。猪支原体肺炎灭活疫苗(GD0503株)适用于预防猪支原体肺炎(猪喘气病),接种后28日产生免疫力,免疫期为6个月。该疫苗产品通过使用猪肺炎支原体GD0503株接种MH培养基,收获培养物经浓缩、纯化、灭活后,加入油佐剂制备而成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"gpt_icon":0},{"id":"2588012347","title":"海正药业(600267.SH)子公司通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2588012347","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588012347?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:42","pubTimestamp":1764754924,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海正药业(600267.SH)发布公告,近日,公司全资子公司海正药业南通有限公司(简称“海正南通公司”)收到江苏省药品监督管理局下发的《药品GMP符合性检查告知书》(苏药监药生告知〔2025〕438号)。本次药品GMP符合性检查中,盐酸米诺环素原料药是上市前的首次药品GMP符合性检查,对应生产线是新建生产线后首次通过GMP符合性检查,截至目前,上述车间相关固定资产累计投入约9,916万元,其中已完成投入约8,630万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0060","BK0239","BK0028","600267"],"gpt_icon":0},{"id":"2588775021","title":"海正药业(600267)披露第四次以集中竞价交易方式回购公司股份的进展公告,12月01日股价下跌0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588775021?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:39","pubTimestamp":1764599942,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,海正药业报收于10.44元,较前一交易日下跌0.1%,最新总市值为125.16亿元。近日,浙江海正药业股份有限公司发布关于第四次以集中竞价交易方式回购公司股份的进展公告。公告显示,公司于2025年5月12日召开董事会及监事会会议,审议通过第四次以集中竞价交易方式回购股份的议案,回购资金总额不低于5000万元且不超过1亿元,回购价格不超过13元/股,回购期限为2025年5月12日至2026年5月11日。2025年11月未实施回购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100037360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"gpt_icon":0},{"id":"2585610515","title":"每周股票复盘:海正药业(600267)拟投建宠物处方粮项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2585610515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585610515?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:45","pubTimestamp":1763840713,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,海正药业报收于10.29元,较上周的11.26元下跌8.61%。本周,海正药业11月17日盘中最高价报11.33元。海正药业当前最新总市值123.36亿元,在化学制药板块市值排名42/151,在两市A股市值排名1459/5167。本周关注点公司公告汇总:同意控股子公司投资建设宠物处方粮项目,总投资2亿元。公司公告汇总浙江海正药业股份有限公司第十届董事会第九次会议审议通过两项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0188","600267","BK0239"],"gpt_icon":0},{"id":"2584891470","title":"海正药业最新公告:控股子公司拟投建宠物处方粮项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2584891470","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584891470?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:34","pubTimestamp":1763544873,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称,公司控股子公司海正动保拟使用自有资金1亿元,在台州市椒江区设立全资子公司并投资建设宠物处方粮项目。项目选址浙江省台州市椒江区,项目投资2亿元,股东出资1亿元,项目分两阶段实施,第一阶段建设期24个月,第二阶段扩建产能并完善配套。项目达产后,预计新增宠物处方粮年产能10000吨。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900028222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0028","BK0239","BK0188","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768296894660,"stockEarnings":[{"period":"1week","weight":0.0323},{"period":"1month","weight":0.0213},{"period":"3month","weight":0.0263},{"period":"6month","weight":-0.1561},{"period":"1year","weight":0.4085},{"period":"ytd","weight":0.0657}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54361人(较上一季度增加5.04%)","perCapita":"22041股","listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","registeredCapital":"119884万元","survey":" 浙江海正药业股份有限公司的主营业务是化学原料药和制剂的研发、生产和销售业务。公司的主要产品是海博麦布片(赛斯美)、注射用哌拉西林钠他唑巴坦钠(特治星)、盐酸米诺环素胶囊(玫满)、瑞舒伐他汀钙片(海舒严)、注射用丝裂霉素、氨氯地平阿托伐他汀钙片(多达一)、丁二磺酸腺苷蛋氨酸肠溶片(喜美欣)、奥利司他、米尔贝肟吡喹酮片(海乐妙)、注射用丁二磺酸腺苷蛋氨酸(喜美欣)。近年来先后承担国家重大新药创制专项课题50余项,获省部级以上科技进步奖10多项,7项发明专利荣获“中国专利优秀奖”,入围浙江省级“科改企业”培育名单。截至报告期末,公司共实现专利申请1481项(国内申请893项,PCT国际申请211项),其中发明专利1376项,实用新型专利99项,外观设计专利6项;拥有授权有效专利508项,其中发明专利413项,实用新型专利90项,外观设计专利5项。报告期内,公司获得工业和信息化部颁发的“国家技术创新示范企业”、浙江省国资委颁发的“2024年度浙江省优秀科改企业”,海正合成生物学项目成功入选浙江省经信厅2025年新兴产业集群强链补链(“415X”集群新质生产力)项目名单。","listedPrice":11.83},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海正药业,600267,海正药业股票,海正药业股票老虎,海正药业股票老虎国际,海正药业行情,海正药业股票行情,海正药业股价,海正药业股市,海正药业股票价格,海正药业股票交易,海正药业股票购买,海正药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}